Introduction:
Flindr Therapeutics BV, an oncology company based in Oss, has secured €20m in Series A financing. The funds will be used to advance the company’s pipeline of first-in-class, small molecule inhibitors for the treatment of cancer, particularly its lead program RNF31.
- The Series A financing round was led by V-Bio Ventures and included participation from international syndicate investors, including Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, and seed investors Oncode Oncology Bridge Fund, Swanbridge, and Brabantse Ontwikkelings Maatschappij (BOM).
- Flindr Therapeutics utilizes the “ImmunoGram Drug Discovery Engine” to identify important drug targets involved in patient clinical response. This approach involves reverse-translating the heterogeneity in tumor-specific and host-specific factors into lab-based biological models.
- The company’s lead program, RNF31, is a first-in-class small molecule inhibitor of RNF31 (also known as HOIP), a protein-stabilizing E3 ubiquitin ligase that is aberrantly activated in solid and hematological malignancies. Preclinical studies have shown promising activity for the drug candidate in ovarian cancer and B-cell lymphoma models.
- In addition to advancing its pipeline, Flindr Therapeutics plans to develop a second program and expand its pipeline using the ImmunoGram Drug Discovery Engine.
- Flindr Therapeutics was founded in 2020 and has collaborations with the Netherlands Cancer Institute, the Oncode Institute, and the lab of Professor Rudi Beyaert at VIB-UGent Center for Inflammation Research.
Conclusion:
Flindr Therapeutics BV has secured €20m in Series A financing to advance its pipeline of first-in-class, small molecule inhibitors for the treatment of cancer. The company’s lead program, RNF31, has shown promising activity in preclinical models, and Flindr Therapeutics plans to use the funds to further develop this program and expand its pipeline. The company’s collaboration with leading research institutes and the use of the ImmunoGram Drug Discovery Engine provide a strong scientific foundation for its drug development efforts.
